Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) fell 6.4% on Monday . The company traded as low as $2.10 and last traded at $2.18. 2,423,800 shares traded hands during trading, an increase of 300% from the average session volume of 605,964 shares. The stock had previously closed at $2.33.

Separately, ValuEngine raised Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.

COPYRIGHT VIOLATION WARNING: “Ampio Pharmaceuticals (AMPE) Shares Down 6.4%” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.